This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
Alfuzosin
Catalog No. T22232 CAS
81403-80-7
Alfuzosin, a quinazoline derivative, is a selective and competitive antagonist of the α1 adrenergic receptor, primarily used to manage benign prostatic hyperplasia (BPH). It effectively targets and mitigates alpha1-adrenoceptor-mediated contraction across prostatic tissues, the prostatic capsule, bladder base, and proximal urethra, reducing muscular tone and easing symptoms linked to BPH. Clinical studies indicate alfuzosin's superiority over placebo for up to 6 months, sustained efficacy with long-term use (up to 30 months), and comparability to prazosin, another alpha 1-adrenoceptor antagonist, in treating BPH symptoms. Recommended oral doses of 7.5 to 10 mg/day, divided, position alfuzosin as a potential first-line treatment for mild to moderate BPH, especially for patients with significant dynamic obstruction. Additionally, alfuzosin serves as an alternative to prostatectomy for patients unable to undergo surgery, offering symptomatic relief during the waiting period for surgical intervention.
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Alfuzosin, a quinazoline derivative, is a selective and competitive antagonist of the α1 adrenergic receptor, primarily used to manage benign prostatic hyperplasia (BPH). It effectively targets and mitigates alpha1-adrenoceptor-mediated contraction across prostatic tissues, the prostatic capsule, bladder base, and proximal urethra, reducing muscular tone and easing symptoms linked to BPH. Clinical studies indicate alfuzosin's superiority over placebo for up to 6 months, sustained efficacy with long-term use (up to 30 months), and comparability to prazosin, another alpha 1-adrenoceptor antagonist, in treating BPH symptoms. Recommended oral doses of 7.5 to 10 mg/day, divided, position alfuzosin as a potential first-line treatment for mild to moderate BPH, especially for patients with significant dynamic obstruction. Additionally, alfuzosin serves as an alternative to prostatectomy for patients unable to undergo surgery, offering symptomatic relief during the waiting period for surgical intervention.
Molecular Weight
389.45
Formula
C19H27N5O4
CAS No.
81403-80-7
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dose Conversion
You can also refer to dose conversion for different animals.
More
Method for preparing DMSO master liquid: mg
drug pre-dissolved in μL DMSO (Master liquid concentration
mg/mL),
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL PEG300, mix and clarify, next add μL
Tween 80,mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL Corn oil,mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.